HONG KONG, Nov 30, 2020 – (ACN Newswire) – Shineway Pharmaceutical (stock code: 2877.HK) recorded 29.4% revenue growth for October 2020 in comparison with the same period last year, as sales of injection products, soft capsule products, granule products, TCM formula granules, and other dosage forms went up 38.9%, 17.4%, 38.1%, 7.9% and 54.0% respectively.
Category: Healthcare
Captiva Verde Land Corp. Announces Solargram Farms’ Completion of Successful New Brunswick Outdoor Cannabis Harvest with One of the Highest Reported THC and Terpene Values in Canada
Captiva Verde Land Corp. (CSE: PWR) (the “Company”), is extremely pleased to announce that Solargram Farms Corporation (“Solargram”), a holder of a Federal Health Canada License to cultivate, test, harvest and sell cannabis, has successfully completed its first large scale cannabis outdoor farm harvest with record THC and terpene results.
First Year Harvest Results
The Solargram cannabis harvest began on September 17th and was completed on October 30th with final processing completed on November 27, 2020. The Solargram team is credited with a final harvest of approximately 13,000 plants over 350,000 square feet of outdoor farm grown canopy resulting in 15,000 kg of wet cannabis. This harvest is ranked as one of Canada’s top single largest, and lowest cost outdoor legal cannabis crop in Canadian history and is also the largest outdoor cannabis crop ever grown and harvested in New Brunswick.
Very Low Cost of Production Results
Exceeding expectations, the year one total grow cost of production, including direct labor and direct materials, were CDN $0.05/gram wet; $0.22/gram dry which ranks as one of the top tier, lowest cost of cannabis production facilities in the Canadian cannabis industry.
Cannabis is a commodity within the CPG (consumer packaging goods) industry. Lowest cost and highest quality wins. Solargram is a major market disruptor and differentiator as its high quality, very low cost of production, allows its planned high cannabinoid full spectrum and distillate oil products to be sold at prices that are produced at a fraction of its competitors’ cost of production. This competitive advantage will allow Solargram to become a leader in the Canadian cannabis market place commencing in 2021.
HIGH THC REPORTED – Independent Laboratory Test Results
Solargram produced and harvested approximately 35 genetics of which its R2 strain, representing 65% of its year one outdoor cannabis crop, produced a COA (certificate of analysis) from an independent laboratory supplier at 21.53% THC and 2.7% terpenes.
The independent THC laboratory results received for the top five genetics produced, representing the harvested crop include:
R2 (21.53%); Bitter Cherry Punch (18.81%); Gelatoz (17.59%);
Black Garlic (18.86%); New York Purple Diesel (19.66%)
These significant high THC results rival and/or exceed indoor cannabis grown facilities in Canada. Independent test results also validate the crop is pesticide and heavy metal free.
100% of the Solargram shares are held in an escrow account to be transferred to Captiva Verde in exchange for 35 Million Captiva Verde shares subject to a tight pooling agreement, and subject to Health Canada approving an in-process application by all the Captiva Verde Officers and Directors to pass a security clearance and CSE approval.
On Behalf of the Board of Directors
“Jeff Ciachurski”
Jeffrey Ciachurski
Chief Executive Officer and Director
Cell: (949) 903-5906
E-mail: westernwind@shaw.ca
Cautionary Note Regarding Forward-Looking Information
This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69147
VIC Rewards and XcelTrip Bring Blockchain-enabled Vitality Packages to Consumers
CEO of XcelTrip, Mr. Gyanendra Khadka, and Dr. Richard Satur, CEO of VIC Rewards, are joining their platforms to challenge the Medical Tourism Marketspace. Together, the business-duo plan to create synergies to take on the ASEAN, Indian and Korean wellness and vitality digital marketspaces. Currently, the two companies are integrating their resources, and working to raise the stakes and bring consumer wellness value to the markets.
The partnership between XcelTrip and VIC Rewards is a unique and promising one. To understand the unique value proposition of their collaboration through VIC Rewards, one has to first look at these two companies separately and then together.
XcelTrip is an OTA Platform that presently accommodates over 2.4 million hotels and 450 flights globally. VIC Marketplace, on the other hand, specializes in wellness, wellbeing, anti-aging, and therefore, vitality products and services. By 2021, VIC Marketplace is projecting over 500 merchants on their platform. Now, through VIC Rewards, the two companies will come together to create and explore the pre-existing wellness market for medical tourism in the ASEAN, Korean and Indian Markets. Not only is South Korea one of the world’s most popular medical tourism destinations, but researchers and respective government ministers are also placing high hopes on the growing medical tourism market of South Korea and India.
Most importantly, consumers are the ones who will benefit the most from this partnership between XcelTrip and VIC Marketplace. The CEO of XcelTrip, Mr. Gyanendra Khadka says, “With VIC Marketplace on board XcelTrip is in the position to offer great consumer value. Imagine being able to tailor a package that specifically meets your schedule, budget, requirements, healthcare objectives, and goals. That is a powerful message for all people, regardless of where they live in the world.”
XcelTrip currently offers 50+ Categories and 20,000+ Products. Via “Vitality Packages” offered through VIC Rewards, consumers will have the freedom to customize their travel packages focusing on their needs and budgets. Now consumers shall not have to abide by generic travel packages offered by travel companies. The respective platforms, which are underpinned by blockchain technology, will also be able to suggest Vitality focused alternative package offerings for Medical Travellers to improve their health and wellness, hence their Vitality. Community members of VIC Rewards and XcelTrip will also get an opportunity to earn healthcare loyal rewards which they can, in turn, spend on their tailored Vitality Packages.
CEO of VIC Rewards, Dr Richard Satur says, “Not only are we planning on offering Vitality packages, but we will also engage partners to offer DeFi related products such as Insurances, Loans and Medical Device Leases. Our partnership with XcelTrip will focus on bringing true value to consumers, who are sometimes patients, through our combined decentralised e-Commerce platforms.”
The partnership currently has a combined community that exceeds 750,000 members. The shared vision of two platforms to offer Vitality Packages and to elevate consumer value via VIC Rewards will go online by the end of 2020!
About VicRewards
The World’s First Dedicated Healthcare Blockchain Company to offer Loyalty Rewards to Consumers and Carers for participating and adhering to their health and wellbeing care plan (Vitality Plan).
Vic Rewards – https://vicrewards.io/about
Facebook – https://www.facebook.com/VICRewards/
Twitter – https://twitter.com/VICRewards
LinkedIn – https://www.linkedin.com/company/vic-rewards/
Instagram – https://www.instagram.com/vic_rewards/
Youtube – https://www.youtube.com/channel/UCfnXmQdAbFIr-_bXNRO1W6g
Telegram – https://t.me/dclinic_io
Medium – https://medium.com/@VICRewards
Reddit – https://www.reddit.com/user/VIC-Rewards
About XcelTrip
XcelTrip.com is the first blockchain-based travel platform, invested by Founder since launch in 2017. The company has now achieved a 500,000+ active user base with over 2.3 million hotels and 450+ airlines to book from. We now accept Bitcoin, Ethereum, Litecoin, Dash, Verge and our own XcelToken plus (XLAB), OMC, Ormeus and many more for travel booking worldwide.
XcelTrip: https://www.xceltrip.com/
Facebook: https://www.facebook.com/XcelTripGo/
Twitter: https://twitter.com/xceltrip
LinkedIn: https://www.linkedin.com/company/xceltrip
Instagram: https://www.instagram.com/xceltrip/
Medium: https://medium.com/@xceltrip_CryptoTravel
Youtube: https://www.youtube.com/channel/UCz50jspk5omNAemibgpoiVg/featured
Taiwan’s Smart Healthcare fascinates buyers at Taiwan Expo 2020 in Thailand
The Taiwan External Trade Development Council (TAITRA) launched the Taiwan Expo 2020 in Thailand physically and virtually with a theme of “Let’s THAI together” on November 4. Since Thailand has contained the COVID-19 pandemic well, a physical exhibition was held at the Rosewood Hotel in Thailand November 4-6, and an online exhibition showcasing products from 180 Taiwanese suppliers was created at https://taiwanexpo.online/en.
Jointly sponsored by Taiwan’s Ministry of Health and Welfare (MHW) and TAITRA, the Taiwan Healthcare Pavilion was built on the Expo’s official website. On this dedicated webpage, there is complete information on Taiwan’s four advanced hospitals and five major manufacturers of smart medical supplies. In coordination with the exhibition, a webinar was held for Taiwanese doctors and experts to share their innovative medical products and services.
In his opening remarks at the kick-off ceremony, TAITRA’s chairman James Huang pointed out that despite the pandemic impact, TAITRA not only will continue to hold the Taiwan Expo in Thailand, but will play a role to bridge the distance between Taiwan and Thailand via digital technology. We are expecting a better Taiwan Expo 2.0 soon to make a breakthrough.
The Taiwan Healthcare Pavilion has housed many Taiwan’s first-rate hospitals. The National Taiwan University Hospital is well-known for its extraordinary achievements in treating children’s craniofacial trauma, skin hemangioma, venous malformation, orofacial cleft, and microtia. The Changhua Christian Hospital, the first smart and green-energy hospital in Taiwan, is happy to share their green ways of construction and operation. Because of the pandemic outbreak, CCH has hosted more than ten anti-pandemic webinars and business matchmaking meetings. As a result, the collaboration between imedtac Co., Ltd. Taiwan and Thonburi Hospital Group Thailand makes possible building smart wards for demonstration in Thailand. The National Cheng Kung University Hospital is now developing precision medicine and AI for use in coronavirus prevention and quarantine. The Taipei Medical University Hospital owns the Asia’s unique ROSA Spine robotic arm, which can help surgeons implant a lumber vertebrae nail precisely in position.
The exhibition gathered Thai distributers interested in food safety, IVD (In Vitro Diagnostic) tests, AI smart healthcare and pulse healthcare systems, who joined online business meetings and requested catalogues and samples. The suppliers, including Taiwan’s Advance Bio-pharmaceutical Inc., TaiHao Medical Inc., Biotegy Corp., Shiny Pacific Biotechnology Co., Ltd. and Sane Health Enterprise Co., Ltd. are looking forward to trade cooperation in the future.
Taiwan has applied internationally reputed high technology to the medical field, and has initiated customized smart medical systems. TAITRA is committed to promoting the smart healthcare for Taiwan and Thailand.
For more information, please contact the Bangkok Taiwan Trade Center.
Media Contact: Tina
bangkok@taitra.org.tw
https://taiwanexpo.online/en
Bangkok Taiwan Trade Center
Tel: +66-2-651-4470, Fax: +66-2-651-5923
Taiwan External Trade Development Council (TAITRA)
Epazz DeskFlex Desk Scheduling Software Will Release Vaccine Management Solution as Part of COVID Compliance Features
Epazz DeskFlex desk and room booking software is adding a vaccine management solution that tracks employees’ COVID-19 vaccination.
Epazz Inc. DeskFlex (OTC: EPAZ), a leading provider of mission-critical cloud-computing software solutions, announced today that DeskFlex’s vaccine management solution will help organizations plan and develop COVID-19 vaccination programs among its team members when it is released.
Pharmaceutical companies are working double-time to create a vaccine against the Novel 2019 Coronavirus. One of the leading pharmaceutical companies, Pfizer, developed a vaccine with a promising result of 90% effectivity according to the company’s clinical results. Over 43,538 volunteers participated and received two injections within 21 days apart. The company claimed that among the 94 evaluable COVID-19 cases, results revealed that more than 90% effectively prevented the Coronavirus infection. This result exceeded the Food and Drug Administration set a 50% minimum effectiveness bar. This promising result will pave the way for mass vaccinations if FDA approves the final stage of testing.
DeskFlex vaccine management software will facilitate the tracking and management of employees’ immunization against the Coronavirus. It allows employees to indicate their vaccination history through the health record management service. With the development of approved COVID-19 vaccines on the way, company administrators can monitor which team member has completed their vaccinations and which employees need a reminder to schedule and receive the COVID-19 vaccine through DeskFlex vaccine management solution.
The Center for Disease Control and Prevention (CDC) and other collaborative health agencies initiated the Immunization Integration Program (IIP) four years ago. After clinicians found it challenging to keep track and improve adult vaccinations, the program started. The program’s goal was to help automate immunization-related tasks with an electronic health record and clinic software systems. Thus, with the digitalization of immunization records and schedules, the program aimed to increase vaccination rates within the adult population and secure these immunization records in cloud-based storage.
DeskFlex desk and room scheduling software solutions pride itself on providing organizations with a comprehensive set of COVID-compliant software features. The launching of DeskFlex’s vaccine management software will further reinforce the workplace’s health and safety measures.
According to Shaun Passley, Ph.D., Chairman, and CEO of Epazz, Inc., “We are optimistic that adding the vaccine management software feature will further secure the workplace and schools from COVID-19 infections. When administrators identify those who haven’t had the vaccine, they can make the appropriate decision to protect the majority.”
About DeskFlex.com
DeskFlex is a desk booking solution and room reservation software useful in booking conference rooms, meeting rooms, workspaces, desks, car parking spaces, and office equipment. DeskFlex meeting room scheduling system helps office managers accommodate remote workers’ time in the office, reducing rent and facility costs. DeskFlex lets employees reserve desks in advance or claim desks right away. It adjusts the telephone switch (PBX), so calls ring at the “desk du jour.” DeskFlex includes check-in, point-and-click floor maps, a web browser, a local kiosk, Outlook integration, and conference room scheduling.
About Epazz, Inc. (www.epazz.com)
Epazz, Inc., is a leading cloud-based software company that specializes in providing customized cloud applications to the corporate world, higher-education institutions, and the public sector. Epazz BoxesOS(TM) v3.0 is a complete web-based software package for small- to mid-size businesses, Fortune 500 enterprises, government agencies, and higher education institutions. BoxesOS provides many of the web-based applications organizations would otherwise need to purchase separately. Epazz’s other products are K9Sky.com kennel software and the Provitrac applicant tracking system.
SAFE HARBOR
This is the “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: certain statements contained in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by the use of forward-looking words such as “may,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” and “continue” (or the negation thereof) or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from future results or those implied by such forward-looking statements. Investors are cautioned that no forward-looking statement is a guarantee of future performance and that actual results may differ materially from those contemplated by such forward-looking statements. Epazz, Inc. assumes no obligation and has no intention of updating these forward-looking statements. It has no obligation to update or correct information prepared by third parties that are not paid for by Epazz, Inc. Investors are encouraged to review Epazz, Inc.’s public filings on SEC.gov and otcmarkets.com, including its unaudited and audited financial statements and its OTC market filings, which contain general business information about the company’s operations, results of operations, and risks associated with the company and its operations.
CONTACT:
For more information, please contact
Investor Relations
investors@epazz.net
(312) 955-8161
www.epazz.com
Olympus announces acquisition of FH ORTHO, an international orthopedics company in France
To expand Minimally Invasive Surgery field by reinforcing its orthopedics business
Olympus Corporation (Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced that it has acquired FH ORTHO SAS, an international orthopedic company headquartered in Heimsbrunn, France, following the close of a definitive agreement the two companies signed in the summer of 2020. The acquisition underscores Olympus’ commitment to expanding in the growing field of orthopedic minimally invasive surgery (MIS) both organically and through mergers and acquisitions, with the overarching goal of developing innovative solutions that improve clinical outcomes, reduce overall costs and enhance quality of life for patients.
By acquiring FH ORTHO, Olympus builds on its portfolio of innovative and patient-focused solutions that are used in MIS procedures in ligament repair, foot & ankle, and trauma surgery.
Olympus is already active in orthopedics in Japan, where its joint venture Olympus Terumo Biomaterials Corp. distributes products such as bone substitutes and high tibial osteotomy (HTO) plates and screws. Beyond this, Olympus has also developed the first ultrasound device indicated for arthroscopic surgery, supporting more accurate and safer cutting of bones.
The acquisition of FH ORTHO will strengthen Olympus group’s sales channels by enabling it to expand the distribution of both Olympus’ orthopedic products via FH ORTHO’s existing distribution channels, as well as to sell certain FH ORTHO key products in Japan.
By expanding its distribution network, Olympus will reinforce its position as a leading global medtech company as it continues to innovate and create solutions across all areas of the MIS workflow.
“We are pleased to integrate FH ORTHO’s product portfolio, market reach and talented people to our orthopedics business,” says Toshihiko Okubo, Senior Vice President, New Business Development, Global at Olympus. “By combining FH ORTHO’s expertise and its excellent business presence with our products and solutions for the minimally invasive orthopedics surgery, the benefit of our offer to the patients and healthcare professionals will be further enhanced across the world.”
Jean-Marc Idier, CEO of FH ORTHO, comments, “The FH ORTHO team very positively welcomes the arrival of Olympus as a recognition of our ongoing efforts and past accomplishments, whilst providing us with new means to accelerate the next phase of our international expansion.”
About FH ORTHO
FH ORTHO develops and manufactures orthopedic devices and instruments for surgeons around the world. Founded in Mulhouse, France in 1964, FH ORTHO is represented in over 37 countries, with products focused on joint reconstruction, ligament repair, biologics, foot & ankle, and trauma surgery. R&D and factory are based in Quimper, France. Backed by 55 years of forward-thinking innovation in devices, techniques and product delivery, the company today is positioned for rapid expansion globally.
With an unrelenting commitment to innovation, research and collaboration, FH ORTHO continues to bring new ideas and techniques to advance the forefront of orthopedics globally. FH ORTHO products are developed and refined by surgeon experts who are among the world leaders in their respective fields. Prized for elegant design and distinguished by clinical sophistication and flexibility, FH ORTHO products help surgeons deliver ideal patient outcomes with devices, systems and tools that simplifies patient management for the surgeon, at an overall cost structure that is a benefit to the entire patient continuum of care.
About Olympus’ Medical business
Olympus’ Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.
For questions or additional information, please contact:
Europe, Middle East and Africa
Matthias Gengenbach
+49 15142369420
matthias.gengenbach@olympus-europa.com
Japan
Yuka Horimoto
+81-90-2490-1071
yuka.horimoto@olympus.com
Avance Clinical Wins MasterControl 2020 Innovation Excellence Award
The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony.
Avance Clinical made the announcement today at AusBiotech 2020 (28 – 30 October, 2020).
https://www.ausbiotechnc.org/
Avance Clinical CEO Yvonne Lungershausen said the company was very pleased to be awarded such recognition by MasterControl, a leader in the clinical digital management technology.
The MasterControl Clinical Excellence solution streamlines eTMF management and helps clients achieve real-time visibility into critical clinical processes across operational teams – all on one centralized platform. https://www.mastercontrol.com/clinical/
“The award acknowledges our leadership as Australia’s biotech CRO and it provides further confidence to our clients that we are serious about delivering quality clinical research services by being nimble and adaptive, and by utilising state-of-the-art systems that are compliant with industry standards, such as MasterControl eQMS,” said Yvonne Lungershausen.
“Avance Clinical invests significantly in the industry’s leading clinical technologies making it one of the most advanced CROs globally for digital clinical research management and eClinical solutions.”
On presenting the Innovation Excellence Award, MasterControl said the award recognises “the power of innovation and celebrates companies who feel the same way we do, who are not afraid to shed the status quo to find their own path and who push boundaries and spearhead important changes within their industries. Companies driven by innovation who truly live and breathe it.”
Avance Clinical Director Quality Assurance, Priyanka Chamoli, said:
“Receiving the award from MasterControl is a testament of our commitment to invest in our Quality Management System and to continually improve and strengthen it. This Award recognises and provides visibility to our efforts to push boundaries and adopt this significant change not just for the Quality Assurance department but across-the-board in the organisation.”
“MasterControl eQMS enables accurate, streamlined processes for Document Control and Training. Avance Clinical, which is on a significant growth trajectory, requires robust procedures as part of our QMS. MasterControl has allowed our staff to create/review and access our controlled documents in real-time and the automated link between different modules enables timely delivery of training.”
Avance Clinical Director Compliance and Training, Lisa Eglinton said:
“MasterControl Training Module provides a robust, user-friendly method for the delivery of role-specific training programs to all staff. The system provides a real-time indication of training status to Trainees and their Line Managers which ensures training compliance across the company.”
Avance Clinical is the leading Australian owned CRO that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.
Considering Australia? Contact us about your next study. https://www.avancecro.com/eclinical-solutions/
See Image here http://bit.ly/AvanceClinicalMasterControl
(From left to right) Priyanka Chamoli, Director Quality Assurance, Emma Woolman, Senior Compliance and Training Officer, Yvonne Lungershausen, Avance Clinical’s CEO, and Lisa Eglinton, Director Compliance and Training.
About Avance Clinical www.avancecro.com
Australia’s Avance Clinical has more than 20-years of experience and is now one of Australia’s leading Contract Research Organizations.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.
The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. eClinical solutions – speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia’s counter-flu and allergy seasons
Media Contact:
media@avancecro.com
Chris Thompson
Agilex Biolabs Client Shasqi Announces Click Chemistry Breakthrough with First-Ever Human Application in Launch of Clinical Program
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, congratulates client company Shasqi on the announcement of the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.
San Francisco-based Shasqi said in the announcement:
First Patients Dosed in Phase 1 Clinical Study of SQ3370 for Advanced Solid Tumor Malignancies
Shasqi is First Y-Combinator Biotech Company to Reach First-in-Human Clinical Studies
Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPACtm) Platform, announced today the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.
The first two patients have been dosed in Shasqi’s Phase 1 clinical study of SQ3370 for the treatment of advanced solid tumors. SQ3370 is a novel investigational product that activates a non-toxic protodrug into a powerful chemotherapy agent, doxorubicin, precisely at a pre-injected tumor. SQ3370 is designed to allow substantially higher drug doses to be given to the patient, increasing tumor destruction while minimizing toxicity in the rest of the body.
“Shasqi is founded on the belief that one day we will be able to beat cancer without poisoning our bodies. We are excited to reach this milestone with our CAPAC Platform and the launch of Shasqi’s first clinical program,” said Jose M. Mejia Oneto, M.D., Ph.D., Founder and CEO of Shasqi.
The CAPAC Platform is a new therapeutic modality based on click chemistry, which leverages biocompatible chemical reactions, to activate protodrugs at a selected tumor that has been pre-injected with a biopolymer. The CAPAC platform is agnostic to tumor characteristics that can vary from patient to patient, such as biomarker expression and enzymatic activity, rendering it applicable to a broad array of tumor types. Additionally, the CAPAC Platform is highly modular and can be applied to a wide variety of cancer therapeutics in addition to doxorubicin.
“Doxorubicin has been proven effective for dozens of cancers, but severe side effects limit its use. Guiding it directly to the tumor while avoiding damage to the rest of the body may allow us to use doxorubicin and potentially many other drugs in a completely new and effective way for patients,” commented Wayne Saville, M.D., Chief Medical Officer of Shasqi. “Shasqi has taken a novel concept through a rigorous preclinical regulatory path all the way to treating patients in near-record time.”
“Shasqi was Y Combinator’s first therapeutic biotechnology investment and now the first of our life sciences companies to reach clinical development,” said Jared Friedman, Partner, Y Combinator. “We are extremely impressed by the team’s rapid advancement and capital-efficient execution. SQ3370 and CAPAC are not just a standard new small molecule, but rather a broad and powerful new platform leveraging state of the art science and materials to transform the treatment of cancer.”
SQ3370-001 (NCT04106492) is a multicenter, first-in-human, dose-escalation, Phase 1 clinical trial evaluating the safety and tolerability, pharmacokinetics, immune effects, and preliminary anti-tumor efficacy of SQ3370 in patients with locally advanced or metastatic solid tumor malignancies ineligible for standard-of-care therapy. The study is being conducted in the United States and Australia at multiple cancer centers, including MD Anderson Cancer Center and Stanford University. The study is expected to be completed in 2021. More information about the trial is available at: https://clinicaltrials.gov/ct2/show/NCT04106492.
See the announcement here. https://tinyurl.com/y2splohj
Agilex Biolabs is known internationally for its continued investment in the latest technology, and for attracting some of the leading scientists from Australia and around the world.
Agilex Biolabs, the only FDA-inspected lab of its type in the region, also features a rebate of up to 43.5% on clinical trial bioanalytical services spend as part of the Australian Government clinical trial attraction program.
Agilex Biolabs’ world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.
The company has recently expanded its labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the New Labs Walkthrough Video Here https://www.agilexbiolabs.com/new-labs-video
Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).
Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
– Immunophenotyping
– Receptor occupancy
– Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
– PBMC assays and cellular mechanism of action assays (eg: ADCC)
Agilex Biolabs has more than 90 staff including 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year they will analyse more than 60,000 samples for pharma/biotechs companies from US, Europe and APAC.
Please Book a Briefing with us before you start your next clinical trial. https://calendly.com/agilexbiolabs/15min
About Agilex Biolabs https://www.agilexbiolabs.com/
Agilex Biolabs, Australia’s leading bioanalytical laboratory, has more than 20 years’ experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. We have successfully supported hundreds of preclinical and clinical trials around the world where customers choose Australia for the streamlined regulatory process and access to the world’s most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.
We offer services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.
Agilex Biolabs Media Contact:
Media@AgilexBiolabs.com
Kate Newton
Shasqi media contact:
David Rosen, Argot Partners
media@shasqi.com
+1 (212) 600-1902
Biotechs get scalable early to late phase clinical offering from Avance Clinical and Cromos Pharma – announced at Bio-Europe 2020
The collaboration allows biotechs to quickly start their pre-IND early phase studies in Australia, then expand to Central/Eastern Europe to access the large patient populations for their Phase 2 and 3 studies.
Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs.
Importantly, the AU/EU model allows biotechs to keep their data and trial management in Australia, and take advantage of the Australian cash rebate of up to 43.5% on clinical trial costs, throughout all study phases, across both regions.
“We are very excited about this model that seamlessly incorporates two of the most compelling and complementary international clinical research hubs for our biotech clients from early to late phase studies,” said Yvonne Lungershausen, CEO of Avance Clinical.
“Our eClinical and early phase expertise is well augmented by Cromos Pharma’s track record in late stage trials and rapid enrollment capabilities,” she continued.
“We have been collaborating with Avance Clinical and referring clients to each other for years,” remarked Vlad Bogin, CEO of Cromos Pharma.
“But it was a true Eureka moment when we realized that combining Australia’s 43.5% tax rebate with Central/Eastern Europe’s unbeatable recruitment rates is a paradigm shift in how clinical trials should be conducted,” he concluded.
Cromos Pharma can access hundreds of millions of patients via more than 2,500 sites in Central/Eastern Europe.
About Cromos Pharma, www.cromospharma.com
Cromos Pharma provides tailored and effective clinical trial solutions to support the development of drugs that transform healthcare. An international CRO with over 15 years’ experience, we offer fully integrated services performing all aspects of clinical trials in all clinical phases and in a wide range of therapeutic areas. Cromos Pharma delivers rapid recruitment and excellent patient retention as well as expert study design and management. Cromos Pharma has strong regional experience in Central and Eastern Europe with global coverage provided by its US bases in Portland, Oregon and Miami, Florida. Cromos Pharma’s European HQ is in Dublin, Ireland. At Cromos Pharma, we know how important your product is. When the stakes are this high, you need a high-performance partner.
Key benefits:
– International expertise combined with in-depth regional knowledge in Central and Eastern Europe (300+ clinical trials conducted in 70+ indications).
– Extensive PI/site and patient network (40,000+ patients enrolled from nearly 2,500 trial sites).
– Unparalleled patient recruitment – our team met or shortened project timelines in 95% of conducted trials.
– Responsible recruitment is supported by Cromos Pharma’s “No Patients-No Payments” initiative – a unique risk-sharing program.
– Extremely short startup timelines (e.g. Georgia where we assure a study launch in less than 2 months).
– Expertise in innovative, generics and biosimilar global studies (NDAs, ANDAs, BLAs, 505b2).
– Regulatory inspections and audits that attest to the highest quality of data: EMA in 2019 (1-week oncology site inspection); FDA in 2017 (2-week oncology site inspection).
– Clinical Development Strategy – we provide expert guidance on study design, favorable venues, local and global landscape to improve study outcomes.
About Avance Clinical, www.avancecro.com
Australia’s Avance Clinical has more than 20-years of experience and is now one of Australia’s leading Contract Research Organizations for biotechs. Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.
The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. eClinical solutions capabilities – speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia’s counter-flu and allergy seasons
Media Contacts:
Avance Clinical
Chris Thompson: media@avancecro.com
Cromos Pharma
Nicola Donnelly: media@cromospharma.com
Waterdrop unveils Latest Reverse Osmosis Water Filtration System for Amazon Prime Day
Waterdrop, with continuous innovation and a passion for perfection, unveiled its latest Reverse Osmosis Water Filtration System at the Amazon Prime Day 2020. The Waterdrop G3 RO Reverse Osmosis Water Filtration System is unique in Certification, Design and User experience.
NSF Certification: Using reverse osmosis filtration technology with a filtration accuracy of 0. 0001 micro-m, the system is Certified against NSF58 for TDS reduction, and effectively removes most impurities including fluoride, TDS, limescale, and heavy metals from tap water.
Smart Design: Instead of storing filtered water in a tank until required (which might be a very long time), the tankless reverse osmosis systems delay purification until the user turns on the faucet and deliver filtered water in seconds. The tankless design also means that people require little space to fit an under-sink water filter in the kitchen. It is the first smart RO system with composite filters and tankless design in the U. S. market. The three filters provide seven stages of filtration. The pre-sediment and carbon block filter is a 3-in-1 filter that functions as that of three filters combined. The Reverse Osmosis membrane filter adopts an innovative design, and the efficiency of the filter equals more than three stages of filtration. Additionally, the activated carbon block filter uses high-precision activated carbon granules made from natural coconut shell, which will also improve the water taste.
User Experience: Its internal pump allows the RO system to offer faster water flow (400 gallons per day). The system can filter a cup of water in about 12 seconds. It can produce pure water quickly. Moreover, compared to traditional RO systems, Waterdrop Reverse Osmosis Water Filtration System saves water waste by 300%. With smart faucets fitted with G3 smart RO systems, it is exceptionally convenient. The smart replacement notice solves this by automatically notifying users when the smart tankless reverse osmosis system’s filters are due for re-placement. The smart TDS monitoring panel on the water purifier shows water quality in real-time. This feature means that G3 RO system can clean itself whenever it is notified, without relying on the owners assistance, who can invest their time in more important things.
Waterdrop joined the big Amazon Prime Day on October 13th/14th with the new G3 RO water filtration system as well as other hot Waterdrop sale products, offering their customers the best Amazon deals with more than 30% off. Amazon Prime Day was the perfect moment to shop for a replacement water filter for the refrigerator as well. Great prices for the best quality filters.
Since Amazon Prime Day is always a fantastic period to shop, enjoying its huge discounts on top items in the Amazon store is not an opportunity anyone wants to miss. Great Waterdrop Prime Day 2020 deals continue, allowing you to have the best water filtration solution system in your home.
Waterdropfilter
Hannah Montgomery
communication@waterdropfilter.com
Telephone: 1-888-352-3558